skip to Main Content

Novel therapeutic opportunities for metabolic diseases and oncology

TES Pharma’s first in class pipeline has delivered novel compounds that are opening new approaches for metabolic diseases and oncology. Our collaboration with Intercept helps drive their leading position in bile acid research. Whilst the collaboration with RASNA is a ground-breaking approach to NPM-1 modulators.

Our internal programmes leverage our extensive and successful experience in the discovery of ligands for unexplored targets and are focused on:

  • NAD+ homeostasis modulators, and
  • Orphan nuclear receptors

In both these areas we collaborate with world-leading centres of excellence that help unravel the biological complexity of these exciting new areas.

Lung cancer cells | TES Pharma
Back To Top